First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
Sarina A Piha-PaulJasgit C SachdevMinal BarvePatricia LoRussoRussell SzmulewitzSapna Pradyuman PatelPrimo N LaraXiaotian ChenBeibei HuKevin J FreiseDimple ModiAnjla SoodJessica E HuttiJohannes WolffBert H O'NeilPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
On the basis of safety and tolerability, mivebresib RP2D is 1.5 mg for the daily schedule, 2.5 mg for 4/7, and 3 mg for M-W-F. Mivebresib has a tolerable safety profile, and stable disease was observed in some patients with malignant solid tumors.